Patent application number | Description | Published |
20110288070 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE - This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein (I), Q, J, L and Z are as defined in the specification. | 11-24-2011 |
20140179678 | METHODS OF TARGETED TREATMENT OF FRONTOTEMPORAL LOBAR DEGENERATION - The present invention provides targeted treatment to subjects suffering from Frontotemporal lobar degeneration through use of FTLD targeted agents, as described in the present invention. In particular, the FTLD targeted agents provided herein demonstrate high brain penetration, which decreases risk issues associated with peripheral administration. Furthermore, the FTLD targeted agents of the present invention, when administered to a subject selected for treatment based on the results of a FTLD diagnostic assay, offer targeted treatment of FTLD. | 06-26-2014 |
20150080325 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE - This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein (I), Q, J, L and Z are as defined in the specification. | 03-19-2015 |
Patent application number | Description | Published |
20100136589 | Methods and Kits for Determining von Willebrand Factor Activity in the Absence of Ristocetin and for Determining the Activity of ADAMTS-13 Protease - Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin. | 06-03-2010 |
20130078652 | METHODS AND KITS FOR DETERMINING VON WILLEBRAND FACTOR ACTIVITY IN THE ABSENCE OF RISTOCETIN AND FOR DETERMINING THE ACTIVITY OF ADAMTS-13 PROTEASE - Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin. | 03-28-2013 |
20130224777 | Screening method for finding samples having antiphospholipid antibodies - The present invention is in the field of coagulation diagnostics and relates to a screening process for finding samples containing antiphospholipid antibodies (lupus anticoagulants), wherein the platelet aggregation-stimulating action of said antiphospholipid antibodies is determined in vitro. | 08-29-2013 |
20130224883 | Method for recognizing interferences in in vitro diagnostic assays - The present invention is in the field of in vitro diagnostics and relates to a method for recognizing interfering disruptive factors, such as heterophile antibodies or rheumatoid factors for example, in a sample. | 08-29-2013 |
20130230868 | Screening process for finding samples having a functionality disorder of the GPIb-von Willebrand factor interaction - The invention relates to a screening process for determining a disordered von Willebrand factor (VWF)-GPIb interaction in a patient's sample. This comprises contacting the sample with isolated GPIbα protein, with VWF protein and with a solid phase associated with an antibody specific for said isolated GPIbα protein, and determining complex formation. | 09-05-2013 |
20140080144 | METHOD FOR DETERMINING PLATELET-ASSOCIATED ANALYTES - The present invention relates to a routine in vitro method for determining platelet-associated analytes, for example VWF, factor XIII, fibrinogen or D-dimer, in a sample of platelet-rich plasma. | 03-20-2014 |
20140242621 | METHOD FOR DETERMINING PROTEIN S ACTIVITY - The invention relates to a method for determining the protein Ca-cofactor activity of protein S, wherein the protein Ca-cofactor activity of protein S is measured in a first reaction volume in the absence of a protein S inhibitor and in a second reaction volume in the presence of a protein S inhibitor. The protein Ca-cofactor activity of protein S is determined by calculating the quotient of the assay result of the first reaction volume and the assay result of the second reaction volume. | 08-28-2014 |